|
|
 |
|
Viewing report
|
|
|
|
Abbott Laboratories Likely to Reap Benefits from Strategic Split
GlobalData, Nov 2011, Pages: 5
Abbott Laboratories Likely to Reap Benefits from Strategic Split - Deal Analysis from GlobalData
Summary
GlobalData, the industry analysis specialist, has released its new report, “Abbott Laboratories Likely to Reap Benefits from Strategic Split”. The report is an essential source of information and analysis on the division of Abbott Laboratories into diversified medical products and research-based pharmaceutical companies. The report provides insights on the rationale of the deal and its strategic implications. Most importantly, the report provides valuable insights on the strategies of pharma companies to deal with the effect of patent cliff. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the pharmaceutical market ahead of the patent cliff. Its scope includes -
- Profiles of the divided companies of Abbott Laboratories
- Rationale behind division of Abbott Laboratories
- Strategic Implications of the spin-off
- Pharma companies juggling between different strategies ahead of patent cliff
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop business strategies by understanding the current business models being followed by the Abbott Laboratories
- Formulate effective business decisions ahead of the patent cliff
- Organize your sales and marketing efforts by identifying the various strategies being followed by the pharmaceutical companies
|
|
|
|
